BGM Group Ltd. BGM Group Ltd.

BGM Group Ltd.

BGM

Rank in Stocks #22616
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in... Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.
Share Price
$8.13
Last synced: 2026-11-17
Market Cap
$50.30M
Change (1 day)
1.50%
Change (1 year)
-8.65%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for BGM Group Ltd. (BGM)
EPS as of March 2026 TTM: $-4.84
According to BGM Group Ltd.'s latest financial reports, its current EPS (TTM) is $-4.84. At the end of 2025 the company had an EPS of $-5.40, an increase over its 2024 EPS of $-6.00.
EPS history for BGM Group Ltd. from 2017 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-4.84 -10.37%
2025 $-5.40 -10.00%
2024 $-6.00 -81.48%
2023 $-32.40 -820.00%
2022 $4.50 -66.67%
2021 $13.50 -37.50%
2020 $21.60 -5.26%
2019 $22.80 2.70%
2018 $22.20 270.00%
2017 $6.00 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 -224.58%
DE
$6.01 -224.13%
DE
$1.53 -131.67%
JP
$3.66 -175.62%
CH
$0.45 -109.30%
IL

Questions about BGM Group Ltd.'s earnings per share (EPS)

What is BGM Group Ltd.'s earnings per share (EPS)?

BGM Group Ltd.'s earnings per share (EPS) over the last twelve months is $-4.84, as of Mar 2026.

What was BGM Group Ltd.'s earnings per share (EPS) in 2025?

In 2025, BGM Group Ltd.'s earnings per share (EPS) was $-5.40, compared with $-6.00 in 2024.

How has BGM Group Ltd.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, BGM Group Ltd.'s earnings per share (EPS) was highest in 2020 ($21.60) and lowest in 2023 ($-32.40).

How does BGM Group Ltd.'s earnings per share (EPS) compare with similar companies?

BGM Group Ltd.'s earnings per share (EPS) ($-4.84) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.